-
The U.S. JPML has consolidated all Tepezza lawsuits over hearing loss before one Northern Illinois federal judge for coordinated pretrial proceedings.
-
A Tepezza hearing loss lawsuit accuses the manufacturer of failing to provide adequate warning about the risks of the thyroid eye disease drug.
-
The FTC has filed a complaint to stop Amgen from acquiring Horizon Therapeutics, saying it would give the manufacturer a monopoly on certain drugs, like Tepezza.
-
Lawsuits continue to be filed against Horizon Pharmaceuticals over their failure to warn patients and doctors about the long term hearing loss side effects from Tepezza.
-
Horizon Therapeutics is urging a panel of federal judges to reject a motion to consolidate Tepezza infusion lawsuits before one judge for coordinated pretrial proceedings.
-
A Tepezza lawsuit claims the Grave's disease treatment caused permanent hearing loss and tinnitus.
-
The U.S. Judicial Panel on Multidistrict Litigation has agreed to hear oral arguments over whether all Tepezza hearing loss lawsuits filed in federal courts nationwide should be centralized and consolidated before one judge for pretrial proceedings.
-
A Tepezza hearing injury lawsuit accuses the manufacturer of failing to provide adequate adverse side effect warnings to patients and the medical community.
-
The FDA has expanded use of Tepezza, a thyroid eye disease drug linked to an increasing number of reports and lawsuits over hearing loss.
-
A Pennsylvania woman says she suffered permanent hearing loss as the result of a series of Tepezza infusions designed to treat her thyroid eye disease.